AIDSVAX


Also found in: Wikipedia.

AIDSVAX

A vaccine produced by VaxGen which failed to protect those receiving the vaccine from developing AIDS, although some data suggested that it may benefit African Americans. VaxGen has continued to expand the trials. The results of the Phase II trials were underwhelming, so VaxGen piggybacked it with the Aventis-Pasteur vaccine, ALVAC-HIV. Data from the combination vaccine, ALVAC-AIDSVAX B/E, has shown an efficacy ranging from 26 to 31% (N Engl J Med 2009; 361: 23, 2209-2220).
References in periodicals archive ?
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
Results from a recent vaccine trial in Thailand demonstrated preliminary efficacy of a combination ALVAC-HIV and AIDSVAX B/E vaccine regimen among a community-based sample consisting mostly of relatively low-risk heterosexuals (Rerks-Ngarm et al.
The decision to proceed with the study was highly controversial as a previous version of the AIDSVAX failed to show any benefit in two previous studies and the ALVAC was considered be insufficiently immunogenic to proceed to an efficacy trial [6].
The first, or "prime" vaccine, known as ALVAC HIV, was developed by sanofi pasteur and the booster vaccine, AIDSVAX B/E, was originally developed by VaxGen and is now licensed to Global Solutions for Infectious Diseases.
The booster dose, AIDSVAX B/E, is a glycoprotein 120 vaccine.
The vaccine is a combination of Sanofi-Aventis ALVAC canary pox vaccine and HIV vaccine AIDSVAX, made by VaxGen, Reuters reported.
AIDSVAX contains a genetically engineered version of a protein on HIV's surface.
The vaccines used during the trials were ALVAC, from Sanofi Pasteur, the vaccine division of French drugmaker Sanofi-Aventis and AIDSVAX, developed by VaxGen Inc.
Racialized bio-medicine, generated difference: The possibility of racial differentials in the efficacy of AIDSVAX.
c) facilitate the technology transfer of AIDSVAX or other mammalian cell culture manufacturing technology from VaxGen to Celltrion, including the provision of on-site training;
The AIDSVAX B/B vaccine uses two parts of the HIV subtype B gp 120 protein.